MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'dimebon'. Sat, 03 Sep 2011 02:42:09 +0100 http://www.medworm.com/index.php?rid=4704958&cid=t_215799_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FhWBKw4PwEO0%2F Top of the morning to you. Gray skies are hovering over the Pharmalot corporate campus this morning, where we are hustling the short people off to the school house for some learning and quaffing our usual cup of stimulation - our flavor today is Mocha Fudge Nut. Please join us. While you do, here are some tidbits from around your universe. We hope your day is productive and rewarding. Meanwhile, let us know of anything interesting or unusual. Have a great one… Study Reveals New Target For Antidepressants (Reuters) Teva MS Pill Reduces Relapses Less Most Injectables (Bloomberg News) Glaxo Moving More Jobs To Scotland (Scotland Herald) FDA Approves Merck Skin Cancer Drug (Reuters) Biogen MS Pill Shows Promise In Study (Associated Press) UK Docs May Consider Cost When Prescribing Off-La... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4704958 Tue, 12 Apr 2011 12:07:42 +0100 4704958 http://www.medworm.com/index.php?rid=3695812&cid=t_215799_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FW93OBM9xY-I%2F Late yesterday, Pfizer suspended all clinical trials of tanezumab, an experimental biotech drug for osteoarthritis, after some patients actually fared worse and had to have joint replacement surgery (see statement). This also means an end to trials for patients without osteoporosis in which the drug was being tested for cancer pain, interstitial cystitis and painful diabetic peripheral neuropathy. Interestingly, this comes a week after Pfizer presented positive data at a medical meeting showing the drug significantly reduced knee pain better than a placebo (see this). This is only the latest in a string of big setbacks for the big drugmaker, starting with torcetrapib, a cholesterol pill that Pfizer hoped would not only revolutionize treatment, but its financial statement. Earlier this year... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3695812 Thu, 24 Jun 2010 12:23:10 +0100 3695812 http://www.medworm.com/index.php?rid=3331373&cid=t_215799_111_f&fid=36048&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FzkSCtSPo-8g%2F Finding a treatment or a cure for Alzheimer’s disease is keeping researchers busy across the world. Unfortunately, they aren’t having a lot of success and the latest hopeful entry has turned out to be a bust. Dimebon, a medication that was developed to help slow the progression of Alzheimers has failed in the latest round of testing of 598 patients with mild to moderate disease. The results shocked the researchers because an earlier, smaller 18-month study of the drug showed that there was improvement among the patients taking Dimebon. The companies that collaborated on the production, Pfizer and Medivation, haven’t given up completely on the drug. They are continuing with four more studies that combine Dimebon with other drugs, as well as one study that is investigating ... A Hearty Life blogs http://www.medworm.com/rss/comments.php?id=3331373 Thu, 04 Mar 2010 17:00:54 +0100 3331373 http://www.medworm.com/index.php?rid=3331439&cid=t_215799_122_f&fid=34755&url=http%3A%2F%2Fneuropsychological.blogspot.com%2F2010%2F03%2Falzheimer-disease-dimebon-results-part.html From The New York Times:Hopes for Alzheimer’s Drug Are DashedBy ANDREW POLLACKPublished: March 4, 2010"The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer."Read the full article (Source: BrainBlog) BrainBlog blogs http://www.medworm.com/rss/comments.php?id=3331439 Thu, 04 Mar 2010 01:23:00 +0100 3331439 http://www.medworm.com/index.php?rid=3331440&cid=t_215799_122_f&fid=34755&url=http%3A%2F%2Fneuropsychological.blogspot.com%2F2010%2F03%2Falzheimer-disease-alzheimers.html A press release from earlier today by Pfizer:Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program[snip] "About the CONNECTION Study"CONNECTION is a Phase 3, multi-national, double-blind, placebo-controlled safety and efficacy trial involving 598 patients with mild-to-moderate AD at 63 sites in North America, Europe, and South America. Patients had a mean age of 74.4 years and a mean score of 17.7 on the Mini-Mental State Examination (MMSE) upon entry into the study. More than 40 percent of the patients enrolled were in the United States. In the study, patients were randomized to one of three treatment groups, receiving dimebon 20 mg three times a day (TID), dimebon 5 mg TID, or placebo TID for six month... BrainBlog blogs http://www.medworm.com/rss/comments.php?id=3331440 Wed, 03 Mar 2010 23:22:00 +0100 3331440 http://www.medworm.com/index.php?rid=3327297&cid=t_215799_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F_fhHsIVocIk%2F Hello, and nice to see you again. A spot of rain here on the Pharmalot corporate campus, but as always, we manage to keep our spirits sunny. Of course, we get help from a cup or two of stimulation, but you already know that. Meanwhile, another day lies ahead and all sorts of adventures await. To help you navigate, here are a few items of interest. Have a good one…. Pfizer Alzheimer’s Drug Fails Phase III Study (Associated Press) Bristol And Allergan Sign Deal For Pain Drug (Reuters) Pfizer To Make Bid For Ratiopharm (Bloomberg News) UK’s NICE Recommends Roche’s RA Drug (Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3327297 Wed, 03 Mar 2010 13:12:51 +0100 3327297 http://www.medworm.com/index.php?rid=3115265&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2F5COKTy-TL-s%2Fdimebon-clinical-trial-and-mom-virtual.html I am receiving emails asking me about the status of the Dimebon clinical trial. By Bob DeMarco Last week my mother completed all the pre-clinical trial testing. As of yesterday they were waiting for the official report from the cardiologist (EKG), and the results of the brain scan. If we don't hear today, it will be next week due to the Holiday schedule. One thing I like about the application process is all the testing. If you don't know this, you have the rights to all the information. In other words, you can have copies of the tests and the results. This is also true throughout the clinical trial. Bottom line right now, I don't know if we are in or not in the clinical trial. Keep in mind, if we get in we only have a 50 percent chance of receiving the drug during the clinical trial... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=3115265 Tue, 22 Dec 2009 18:36:40 +0100 3115265 http://www.medworm.com/index.php?rid=3008378&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FxunYdXeJMV8%2Fmedivation-starts-new-clinical-trials.html When people find out that I once worked in a Wall Street firm they often ask me what stocks they should be buying. They also ask which Alzheimer's stock they should buy......I am not in the habit of recommending stocks. Its not my job. So I'll start by saying this is not a recommendation. On the other hand, the site statistics indicate that a large fraction of the readers that come to this website are interested in investing. I wanted to bring this into you awareness, but it is up to you to decided which investments are appropriate for you. Full disclosure: I am in the process of determining if my mother is a candidate for the Dimebon with Namenda clinical trial. Protocol Number: B1451006 No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-se... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=3008378 Thu, 19 Nov 2009 14:51:18 +0100 3008378 http://www.medworm.com/index.php?rid=2985004&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FmMBexF6Fpeg%2Faricept-out-namenda-in-dimebon-next.html Bye Bye Aricept -- Is Dimebon in our future..... I took my mother off Aricept yesterday. She continues on Namenda. After two months my mother will be eligible for the Dimebon clinical trial that interests us. I had her tested yesterday, so I know where we stand. She has experienced a slow steady decline over the last three years. We are getting close to what I would personally describe... Comments, feedback, additional advice welcome. (Source: Alzheimer's Reading Room, The) Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2985004 Wed, 11 Nov 2009 20:02:13 +0100 2985004 http://www.medworm.com/index.php?rid=2963309&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2F15WB71zKhMc%2Fdimebon-contact-and-constellation.html Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD).The CONTACT study will... Comments and sharing welcome. (Source: Alzheimer's Reading Room, The) Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2963309 Wed, 04 Nov 2009 19:47:56 +0100 2963309 http://www.medworm.com/index.php?rid=2899175&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FtYIVEd5uhEc%2Fnew-dimebon-clinical-trial-coming-soon.html A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin is currently scheduled and will soon be accepting new participants. This is a phase one clinical trial. By Bob DeMarco Alzheimer's Reading Room Editor Purpose To estimate the absorption, safety, and tolerability of a dimebon transdermal solution relative to the dimebon immediate release oral formulation. Subscribe to The Alzheimer's Reading Room--via Email Eligibility Ages Eligible for Study: 50 Years to 85 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: Yes Inclusion Criteria: Caucasian, male or females, 50 to 85 years inclusive. Subjects must have adequate space available on each side of the upper or middle back that is free from excessive hair, broken or irrita... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2899175 Thu, 15 Oct 2009 19:49:20 +0100 2899175 http://www.medworm.com/index.php?rid=2766282&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2F_HP7sO6SnS4%2Fnew-dimebon-clinical-trial-now.html A new Dimebon Phase 3 clinical trial is now open and recruiting new participants. The study is called--A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease.  Inclusion Criteria: Men and women ≥ 50 years of age with a diagnosis of Alzheimers disease. Have a Mini-Mental State Exam between 5 and 14 inclusive. Have been taking the medication memantine (ie., Namenda) for at least six months prior to this study. Must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care. Exclusion Criteria: Have taken medicines for Alzheimers disease other than memantine (e.g., donepezil, r... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2766282 Thu, 03 Sep 2009 18:47:00 +0100 2766282 http://www.medworm.com/index.php?rid=2664098&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FIiGZ978GmCk%2Fmost-popular-articles-on-alzheimers.html Test Your Memory (TYM) for Alzheimer's or Dementia in Five MinutesA new cognitive test for detecting Alzheimer's disease is quicker and more accurate than many current tests, and could help diagnose early Alzheimer's, dementia, or mild cognitive impairment.Go here to continue reading.The Mini-Cog Test for Alzheimer's and DementiaThe Mini-Cog is a simple five minute test that is useful in detecting mild cognitive impairment, dementia, or an early stage of Alzheimer's. The research study, included below, showed that the test has a high degree of accuracy (83 percent).Go here to continue reading.A Simple Three Minute Test Can Detect the Earliest Stage of Alzheimer's DiseaseThe study shows that the combination of a very brief three-minute cognitive screening test, called the Mini-Cog (MC), wit... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2664098 Sun, 02 Aug 2009 15:08:39 +0100 2664098 http://www.medworm.com/index.php?rid=2637987&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FBzaQKwkumYg%2Fnote-from-our-reader-on-dimebon.html Our reader Lou started the Dimebon clinical trial just over a week ago. He sent me an email and said, ...it isstunning how quickly my faculties have improved. Speech, memory, andintellect seem to be significantly improved.This is great news, Lou. Keep us informed on how you are progressing.Also see Medivation Dimebon Connection Study Complete, Additional Phase 3 Trials Still OpenAll 19 Dimebon clinical trials and status.Join UsSubscribe to The Alzheimer's Reading Room Bob DeMarco is an Alzheimer's caregiver and editor of the Alzheimer's Reading Room. The Alzheimer's Reading Room is the number one website on the Internet for advice and insight into Alzheimer's disease. Bob taught at the University of Georgia, was an executive at Bear Stearns, the CEO of IP Group, and is a mentor. He has wri... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2637987 Fri, 24 Jul 2009 14:20:24 +0100 2637987 http://www.medworm.com/index.php?rid=2611155&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FqeHkbLdwt6k%2Fmedivation-dimebon-active-clinical.html The Google keyword search "Dimebon" brings visitors to the Alzheimer's Reading Room every day. It is easy for me to understand why. Dimebon is the search for the "holy grail" when it comes to a cure or treatment for Alzheimer's disease.If you want to find all the active clinical trials for Dimebon (Medivation) go here.If you want to see all the clinical trials for Dimebon--recruiting, not yet recruiting, active but not recruiting, and completed--go here.If you are thinking about applying for a clinical trial--go for it. There is no downside and the process is easy and non-threatening. Call the number on the clinical trial page, and if you are qualified go in for the initial interview.Join UsSubscribe to The Alzheimer's Reading RoomPfizer and Medivation Present Positive Safety and Tolerabil... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2611155 Thu, 16 Jul 2009 20:13:22 +0100 2611155 http://www.medworm.com/index.php?rid=2606201&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FZ2mmDsqxq-s%2Fdimebolin-increases-brain-beta-amyloid.html "This result is highly unexpected in what may prove to be a clinically beneficial Alzheimer's drug," Samuel Gandy said. "We need more research to further clarify how dimebolin affects beta amyloid levels in the brain.""A number of ideas need to be pursued. It may turn out that the drug works by getting toxic amyloid out of brain nerve cells. Or, the effects of dimebolin on other brain systems may override its effect on increasing beta amyloid. Finally, the drug's beneficial actions might have nothing to do with amyloid, which, if true, indicates the existence of important therapeutic targets independent of beta amyloid," Gandy added.For more Insight into Alzheimer's DiseaseSubscribe to The Alzheimer's Reading RoomSurprisingly, Dimebolin Increases Brain Beta Amyloid in Alzheimer's Mouse Mod... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2606201 Thu, 16 Jul 2009 01:06:36 +0100 2606201 http://www.medworm.com/index.php?rid=2602198&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FZ2mmDsqxq-s%2Fdimebolin-increases-brain-beta-amyloid.html "This result is highly unexpected in what may prove to be a clinically beneficial Alzheimer's drug," Samuel Gandy said. "We need more research to further clarify how dimebolin affects beta amyloid levels in the brain.""A number of ideas need to be pursued. It may turn out that the drug works by getting toxic amyloid out of brain nerve cells. Or, the effects of dimebolin on other brain systems may override its effect on increasing beta amyloid. Finally, the drug's beneficial actions might have nothing to do with amyloid, which, if true, indicates the existence of important therapeutic targets independent of beta amyloid," Gandy added.For more Insight into Alzheimer's DiseaseSubscribe to The Alzheimer's Reading RoomSurprisingly, Dimebolin Increases Brain Beta Amyloid in Alzheimer's Mouse Mod... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2602198 Wed, 15 Jul 2009 11:46:29 +0100 2602198 http://www.medworm.com/index.php?rid=2553214&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FX1QIzOsl0SE%2Ffarmed-fish-may-pose-risk-for-mad-cow.html The number of articles about the safety of eating farmed fish and mad cow disease (Creutzfeldt Jakob disease) are growing fast on the Internet.This was triggered by a recent study published in the Journal of Alzheimer’s Disease by University of Louisville neurologist Robert P. Friedland.Creutzfeldt Jakob disease is commonly known as mad cow disease. Creutzfeldt Jakob is a disease for which there is no treatment and it is fatal. The diseases can be contracted by eating parts of an animal infected with bovine spongiform encephalopathy (BSE or mad cow disease).You might recall that an outbreak of "mad cow" in England set off quite a reaction several years ago. There was a good result as many countries outlawed feeding rendered cow material to other cattle because the disease is so easily sp... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2553214 Mon, 29 Jun 2009 14:54:21 +0100 2553214 http://www.medworm.com/index.php?rid=2474102&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FWFyNFlGabYc%2Fdimebon-connection-study-complete.html Medivation, Inc. (MDVN) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's disease.The following Dimebon Clinical Phase Three Clinical Trials are open to new participants or scheduled to open.A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's DiseaseIf on existing anti-dementia therapy, have been on a stable dose of anti-dementia therapy (cholinesterase inhibitors and/or memantine) for at least 60 days prior to dosing in study.If not taking existing anti-dementia therapy, have not received therapy with cholinesterase inhibitors and/or memantine within 60 days prior to dosing i... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2474102 Fri, 12 Jun 2009 00:15:28 +0100 2474102 http://www.medworm.com/index.php?rid=2453114&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FeMf8TFt9qVU%2Fdimebon-clinical-trial-massachusetts.html Bonnie left this comment on a Dimebon article that is buried in the archives. I thought I would bring this upfront for our readers in Massachusetts.We are getting a lot of hits via Google search on our various articles on Dimebon. Here is the comment she posted.I am a Clinical Research Coordinator in Massachusetts. I am currently enrolling patients into the Phase 3 trial that was mentioned.Please do not hesitate to contact me to learn more about this trial. bonnie@crccc.com At least 7 readers have contacted me to let me know they are seeking participation in the Dimebon Clinical Trial.Thanks Bonnie.For more Insight into Alzheimer's DiseaseSubscribe to The Alzheimer's Reading RoomBob DeMarco is an Alzheimer's caregiver and editor of the Alzheimer's Reading Room. The Alzheimer's Reading Room... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2453114 Thu, 04 Jun 2009 16:14:14 +0100 2453114 http://www.medworm.com/index.php?rid=2442635&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2Fx58u0tz4mec%2Fanother-dimebon-phase-iii-clinical.html If you are taking cholinesterase inhibitors and/or memantine you will not qualify for the Dimebon Connection study. However, there is another Dimebon clinical trial that has these inclusion criteria:Diagnosis of Alzheimer's Disease.MMSE 12-26 inclusive.If on existing anti-dementia therapy, have been on a stable dose of anti-dementia therapy (cholinesterase inhibitors and/or memantine) for at least 60 days prior to dosing in study.If not taking existing anti-dementia therapy, have not received therapy with cholinesterase inhibitors and/or memantine within 60 days prior to dosing in this study.The study is currently recruiting new participants. For all the specifics including locations go here.A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate A... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2442635 Sat, 23 May 2009 18:42:00 +0100 2442635 http://www.medworm.com/index.php?rid=2442636&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2F8xsFlxJbFfk%2Fdimebon-might-alter-alzheimers-care.html Dimebon is an orally-available, small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer’s. Dimebon is a potential treatment for Alzheimer's and other neurodegenerative diseases. Based on clinical and preclinical data generated to date, Medivation believes that Dimebon works through a novel mechanism of action improving mitochondria function. David Hung, the CEO of Medivation, said on Friday that the experimental drug Dimebon has the potential to transform care for Alzheimer's. The company believes that when the drug achieves FDA approval, it will experience blockbuster sales. The size of the market for Alzheimer's drug sales, now dominated by Aricept, is currently estimated at $5 billion annually."If we can get a drug out onto the marke... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2442636 Sat, 23 May 2009 18:41:03 +0100 2442636 http://www.medworm.com/index.php?rid=2349591&cid=t_215799_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FirwkWfECNiM%2Fdimebon-added-to-donepezil-in-patients.html --New 12-month study broadens Phase 3 clinical program to further evaluate the benefits of Dimebon in Alzheimer's Disease--The CONCERT study is part of a broad, Phase 3 clinical development program for Dimebon. The study builds on data from a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated. CONCERT is designed to complement previous and ongoing studies by further evaluating the efficacy of Dimebon. The Phase 3 program also includes the confirmatory 6-month CONNECTION study, which is designed to evaluate the safety and efficacy of Dimebon monotherapy in patients with mild-to-moderate AD and builds on results of the first pivotal trial of Dimebon in AD. "Due to the complexity of Alzheimer's disease, the condition often... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2349591 Fri, 17 Apr 2009 19:59:55 +0100 2349591 http://www.medworm.com/index.php?rid=2011551&cid=t_215799_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F473714236%2F Once again, the TV drama makes a bid for being renamed Boston Pharmaceutical. In the latest episode of this dressed-up soap opera, a leading character at the Brahmin law firm played by William Shatner is diagnosed with moderate Alzheimer’s and wants to get an experimental Pfizer drug, which appears to be Dimebon. But Shatner is denied - his doctor won’t get the drug for him and the clinical trial appears to be closed. And so he goes to court, where the judge is sympathetic: “A patient, even a dying patient, has no constitutional right to an experimental treatment. Do I agree with that precedent? Not really.” Even so, she boots the case, which the US Supreme Court agrees to hear, although in real life, we know the court earlier this year refused this morning to revie... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2011551 Wed, 03 Dec 2008 15:49:21 +0100 2011551